KOSDAQFood & Beverage353190

Hurum

₩1,334▼ 8.94%2026-11-18 close
Market Cap
₩10.5B
Turnover
₩300M
Volume
230K
Shares out.
7.9M
PER
—
PBR
0.3×
EPS
-₩27
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Prices as of the 2026-11-18 close

01

Report overview

Quarterly Turn to Profit Meets Balance-Sheet and Listing Watch

Hurum returned to operating profit in the third quarter of 2026, but its debt ratio rose to 113.8% at the end of 2025, and the Korea Exchange has said the stock could be designated a managed issue on a market-capitalization basis.

  1. 1

    Annual sales rose from KRW 66.9 billion in 2022 to KRW 99 billion in 2025, but growth slowed to 0.9% in 2025.

  2. 2

    Operating profit reached KRW 1.87 billion in 2025, up 78.6%, yet the operating margin stayed at 1.9%.

  3. 3

    Operating profit turned positive at KRW 93.39 million in the third quarter of 2026, while net losses attributable to controlling shareholders totaled KRW 170 million over the last four quarters.

  4. 4

    The debt ratio climbed from 63.6% in 2022 to 113.8% in 2025, and in November 2026 the company repurchased KRW 12 billion of its third convertible bond before maturity.

  5. 5

    The Korea Exchange said that as of November 12, 2026, market capitalization had stayed below KRW 20 billion for 25 consecutive trading days and could lead to designation as a managed issue.

02

Business structure

Hurum is a specialist company centered on health functional foods. Its core health functional food business is being run with an emphasis on widening sales channels and products, and a securities firm report described it as holding up relatively well even though the health functional food market is weak.

Its consolidated subsidiaries include a filler subsidiary, and a recent securities firm report highlighted that filler sales are growing rapidly. A manufacturing affiliate is also cited as a contributor to revenue.

In its corporate value enhancement plan disclosed on March 26, 2026, the company set out business diversification through new businesses and overseas exports, along with better production efficiency and integrated logistics.

It also said affiliates would open their domestic and overseas distribution channels to each other to pursue shelf placement and joint promotions.

At an extraordinary shareholders meeting on October 7, 2026, five additional business purposes were approved, including sales of bio-material products, medical device wholesale and retail, warehousing and logistics agency, marketing agency, and software development.

The company said the purpose is to expand business areas and secure new growth drivers. The filler market is seeing rising demand while treatment prices are falling, and some analysts expect growth to be led by emerging markets in Asia and Eastern Europe.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩26.3B₩7,040,1060.0%
2025Q4₩23.5B₩1B4.4%
2026Q1₩23B-₩200M−1.0%
2026Q2₩22B-₩800M−3.7%
2026Q3₩23.7B₩93,387,9740.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩66.9B-₩1.7B-₩1.3B−2.5%−3.9%63.6%
2023₩88.4B₩3.8B₩3.3B4.2%8.5%84.0%
2024₩98.2B₩1B₩1.8B1.1%4.2%96.6%
2025₩99B₩1.9B₩1.2B1.9%2.7%113.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Per the DART periodic reports, annual sales were KRW 66.9 billion in 2022, KRW 88.4 billion in 2023 (up 32.1% year on year), KRW 98.2 billion in 2024 (up 11.0%), and KRW 99 billion in 2025 (up 0.9%).

Sales have grown for three consecutive years from 2023 through 2025, and 2025 is the largest year in the 2022 to 2025 span. Growth slowed to 0.9% in 2025.

Operating results moved from an operating loss of KRW 1.7 billion in 2022 to operating profit of KRW 3.76 billion in 2023, a turn to profit, then fell 72.0% to KRW 1.05 billion in 2024 before recovering 78.6% to KRW 1.87 billion in 2025.

The operating margin was -2.5% in 2022, 4.2% in 2023, 1.1% in 2024, and 1.9% in 2025, so margins have stayed low since the 2023 peak.

Net profit attributable to controlling shareholders went from a net loss of KRW 1.32 billion in 2022 to KRW 3.27 billion in 2023, a turn to profit, then fell 46.3% to KRW 1.76 billion in 2024 and 33.9% to KRW 1.16 billion in 2025, two consecutive years of decline.

Consolidated net income including non-controlling interests was KRW 958 million in 2025, a different figure from the controlling-shareholder number. At year-end 2025, total equity was KRW 46.3 billion, of which KRW 42.7 billion belonged to controlling shareholders, and total liabilities were KRW 52.7 billion.

The debt ratio rose from 63.6% in 2022 to 84.0% in 2023, 96.6% in 2024, and 113.8% in 2025. Operating cash flow was KRW 2.83 billion in 2023 and KRW 3.31 billion in 2024, then fell to KRW 75.86 million in 2025.

Quarterly, sales were KRW 26.3 billion in the third quarter of 2025 with operating profit of KRW 7.04 million and a net loss attributable to controlling shareholders of KRW 540 million.

In the fourth quarter of 2025, sales were KRW 23.5 billion, operating profit KRW 1.04 billion, and net profit attributable to controlling shareholders KRW 114 million, a turn to profit.

In the first quarter of 2026, sales were KRW 23 billion with an operating loss of KRW 219 million, and in the second quarter sales were KRW 22 billion with an operating loss of KRW 813 million.

Third-quarter 2026 sales were KRW 23.7 billion, up 8.1% from the prior quarter, and operating profit turned positive at KRW 93.39 million, though the net loss attributable to controlling shareholders stayed at KRW 178 million.

Securities firm reports cited growth at the filler subsidiary and sales contributions from a manufacturing affiliate as the main growth drivers.

05

Industry analysis

Hurum operates in the health functional food market, which securities firm reports describe as weak. Within that backdrop, Hurum has been described as holding up relatively well in its industry on the back of channel expansion and product diversification.

This assessment is a qualitative description from securities firm reports, and no numerical peer comparison is included here. One analysis points to rising demand in the filler market alongside falling treatment prices.

In that setting, a key variable is whether the filler subsidiary can offset lower prices with higher volumes. Growth expected in emerging markets such as Asia and Eastern Europe also aligns with the direction of the subsidiary's overseas sales.

The 2026 corporate value enhancement plan lists building a global marketing base and identifying export hub countries as tasks. How much the export share grows while the domestic health functional food market is weak will shape the company's position.

Within the food and beverage sector, Hurum's sales scale is small compared with large listed peers. Whether shared channels between affiliates translate into higher sales is therefore the starting point for assessing its position.

06

Outlook

The corporate value enhancement plan the company disclosed in March 2026 sets out revenue expansion, profit-focused management, and shareholder value as directions, without quantitative targets.

Its execution tasks are finding export hub countries, improving production efficiency, integrating logistics, and opening distribution channels between affiliates. Whether production and logistics gains show up in the operating margin is the next checkpoint.

The new business purposes approved at the October 2026 extraordinary shareholders meeting cover bio-materials, medical device distribution, logistics agency, marketing agency, and software development, which provide a basis for widening the business scope.

Whether the operating profit turn in the third quarter of 2026 carries into subsequent quarters matters. On November 11, 2026, KRW 1 billion of the second convertible bond was repurchased before maturity, and on November 18, 2026, KRW 12 billion of the third convertible bond was acquired over the counter.

The company reported zero remaining principal on the third bond, and the purchase was funded with own cash and borrowings. Fewer convertible bonds outstanding eases dilution concerns, but higher borrowings could add to financial burden.

The Korea Exchange said market capitalization had been below KRW 20 billion for 25 consecutive trading days as of November 12, 2026, and that a managed issue designation is possible if the condition continues for five more trading days. A 5-for-1 share consolidation took effect in April 2026, when trading was suspended.

07

Valuation

PER
—
PBR
0.3×
ROE
-0.4%
EPS
-₩27
BPS
₩4,978
Dividend per share
—

Because net losses attributable to controlling shareholders over the last four quarters have been recorded, the PER cannot be calculated. For that reason, the comparison centers on the share price relative to net asset value. On a price-to-book basis, the stock trades well below book value per share.

Much of the equity is book value, however, and whether this gap converts into realizable asset value depends on profit recovery. On dividends, the payout ratio for 2025 was disclosed at 271.3%, a level above that year's earnings.

The March 2026 annual shareholders meeting approved a cash dividend, and the company said it will continue dividends based on stable profit growth. Because the 2025 dividend exceeded that year's profit, dividend sustainability should be read alongside profit recovery.

Around 2024 the PER was below the sector average, but accumulated losses now prevent the same comparison from holding. The market capitalization is also near the KRW 20 billion level tied to the managed issue standard, which is a factor in interpreting the share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Signs of a quarterly turnaround

Operating profit reached KRW 1.04 billion in the fourth quarter of 2025, a large improvement from the prior quarter, and net profit attributable to controlling shareholders also turned positive. Operating profit turned positive at KRW 93.39 million in the third quarter of 2026, up 1,226.5% year on year.

The recovery direction after the operating losses of the first and second quarters of 2026 is cited as a bullish factor.

Filler subsidiary growth and channel diversification

Securities firm reports described Hurum's growth as standing out in its industry despite a weak health functional food market. The steep sales growth at the filler subsidiary was also highlighted.

The assessment that the core business is holding up through channel diversification is read as one pillar of earnings recovery.

Share price below book value and stated shareholder returns

In its March 2026 corporate value enhancement plan, the company said it would keep pursuing dividends based on stable profit growth. The approval of a cash dividend at the March 2026 annual shareholders meeting is also a shareholder-return factor.

09

Bear factors

Annual earnings base remains thin

The 2025 operating margin was a low 1.9%, and sales growth slowed to 0.9%. Net profit attributable to controlling shareholders declined in both 2024 and 2025.

Net losses attributable to controlling shareholders over the last four quarters totaled KRW 170 million, so whether quarterly profit turns translate into full-year recovery remains to be seen.

Rising debt and a high payout ratio

The debt ratio rose from 63.6% in 2022 to 113.8% in 2025, and total liabilities were KRW 52.7 billion at year-end 2025. Operating cash flow fell to KRW 75.86 million in 2025.

The 2025 payout ratio was disclosed at 271.3%, and part of the funding for the KRW 12 billion third convertible bond repurchase came from borrowings.

Listing criteria and trading volatility

The Korea Exchange said market capitalization had been below KRW 20 billion for 25 consecutive trading days as of November 12, 2026. If the condition continues, the stock could be designated a managed issue.

On October 20, 2026, it was designated a caution stock for one day due to trading concentrated in a small number of accounts, after the share price fell 15.17% over the prior three trading days.

10

Risk factors

Financial structure

The debt ratio rose from 63.6% in 2022 to 113.8% in 2025. Because part of the convertible bond repurchase was funded with borrowings, interest burden and liquidity management are challenges. The drop in operating cash flow to KRW 75.86 million in 2025 also needs monitoring as a gauge of funding capacity.

Listing maintenance criteria

Under the Korea Exchange rule, a market capitalization below KRW 20 billion sustained for 30 consecutive trading days leads to designation as a managed issue. The exchange reported 25 consecutive trading days as of November 12, 2026.

Whether a designation follows should be checked in exchange disclosures, and designation could affect trading and financing conditions.

Business environment and overseas expansion

Securities firm reports describe the health functional food market as weak, and filler treatment prices are falling. If overseas export expansion and new business execution in the corporate value enhancement plan proceed slower than expected, top-line growth could be limited.

Whether the effects of production efficiency and logistics integration show up in the operating margin also needs checking.

11

What to watch next

  1. After November 20, 2026

    Whether the Korea Exchange designates the stock as a managed issue. The test is whether market capitalization stays below KRW 20 billion for 30 consecutive trading days, and designation would change trading conditions.

  2. Around mid-March 2027

    Annual report for 2026. The 2025 annual report was submitted on March 18, 2026, and it will contain fourth-quarter and full-year 2026 results. Whether the 2026 operating margin improves from 1.9% in 2025 is the next checkpoint.

  3. Around late March 2027

    The 2027 annual shareholders meeting. The cash dividend was approved at the March 26, 2026 meeting, so the dividend decision and its size will show the direction of shareholder returns.

  4. Before May 15, 2027

    The filing deadline for the first-quarter 2027 quarterly report. It is the point at which borrowing levels after the third convertible bond repurchase and filler subsidiary sales can be checked on a quarterly basis.

12

Overall view

Hurum's sales reached KRW 99 billion in 2025, higher than in 2022, but growth slowed to 0.9% and the operating margin stayed at 1.9%. Operating profit turned positive at KRW 93.39 million in the third quarter of 2026, a sign of improvement after the operating losses earlier in the year.

However, net losses attributable to controlling shareholders over the last four quarters totaled KRW 170 million, and the PER cannot be calculated. The debt ratio rose to 113.8% in 2025, and the 2025 payout ratio was disclosed at 271.3%, so financial capacity and dividend sustainability both need monitoring.

Filler subsidiary growth and channel diversification are cited as supporting factors, while the weak health functional food market and falling filler treatment prices are headwinds.

The Korea Exchange said market capitalization had been below KRW 20 billion for 25 consecutive trading days as of November 12, 2026, so whether a managed issue designation follows is the nearest item to confirm.

The next checkpoints are the managed issue decision, the full-year operating margin in the 2026 annual report, and the dividend decision at the 2027 annual shareholders meeting.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.fnguide.com
  2. comp.fnguide.com
  3. digitaltoday.co.kr
  4. news.nate.com
  5. edaily.co.kr
  6. digitaltoday.co.kr
  7. newsprime.co.kr
  8. m.thinkpool.com
  9. digitaltoday.co.kr
  10. vegannews.co.kr
  11. news.nate.com
  12. topstarnews.net
  13. topstarnews.net
  14. topstarnews.net
  15. m.news.nate.com
  16. view.asiae.co.kr

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis